Ultime notizie per CLPS (NASDAQ:CLPS) Azioni

CLPS

CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.

CLPS Inc

JP Morgan analyst Ranjan Sharma downgrades Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) from Overweight to Neutral and lowers the price target from $160 to $135.

News

Downgrades

Price Target

Analyst Ratings

JP Morgan Downgrades Sea to Neutral, Lowers Price Target to $135

B. Riley Securities analyst Yuan Zhi maintains Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) with a Buy and lowers the price target from $19 to $17.

B. Riley Securities Maintains Buy on Mirion Technologies, Lowers Price Target to $17

JP Morgan analyst Ranjan Sharma maintains Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) with a Overweight and lowers the price target from $5.6 to $5.3.

GRAB

JP Morgan Maintains Overweight on Grab Holdings, Lowers Price Target to $5.3

The European Commission (EC) on Tuesday approved Eisai Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and Biogen Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) amyloid-beta (Aβ) monoclonal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">antibody Leqembi&nbsp;(lecanemab)</a>,
The Commission said it <a target="_blank" href="https://ec.europa.eu/newsroom/sante/items/879055/en" rel="noreferrer noopener">granted</a> the approval under strict conditions.
Lecanemab is indicated for adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44829126/leqembi-lecanemab-is-the-first-medicine-that-slows-progression-of-early-alzheimers-disease-to-be-a" rel="noreferrer noopener">confirmed amyloid pathology</a>.
Lecanemab is the only approved Aβ monoclonal antibody that preferentially binds and clears toxic protofibrils&nbsp;(soluble Aβ aggregates) and targets and reduces Aβ plaques (insoluble Aβ aggregates).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
Protofibrils are a key toxic form of Aβ that accumulate in the brain and cause neuronal injury.
MCI due to AD and AD dementia currently affect an estimated 15.2 million and 6.9 million people in Europe, respectively.
Eisai leads lecanemab&#8217;s development and regulatory submissions globally. Biogen and Eisai co-commercialize and co-promote the product. Eisai has final decision-making authority.
In the EU (excluding the Nordic countries), Eisai and Biogen will co-promote the medicine, with Eisai distributing the product as the MA Holder.
In the Nordic countries, Eisai and BioArctic will co-promote the medicine, with Eisai distributing the product as the marketing application holder Holder.
In July 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39985709/biogeneisais-alzheimers-drug-leqembi-gets-no-go-from-european-drug-regulators-advisory-panel-cite" rel="noreferrer noopener">lecanemab approval</a>.
The committee&nbsp;<a target="_blank" href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">considered</a> that the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine, in particular, the frequent occurrence of amyloid-related imaging abnormalities involving swelling and potential bleedings in the brain of patients who received Leqembi.
After re-examining its <a target="_blank" href="https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-alzheimers-disease" rel="noreferrer noopener">initial</a> opinion, in November 2024, CHMP recommended granting marketing authorization.
Earlier this year, the FDA accepted Eisai and Biogen&#8217;s Biologics License Application (BLA) for lecanemab subcutaneous autoinjector for <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42973945/fda-to-review-under-the-skin-weekly-autoinjector-for-biogen-eisais-alzheimers-drug-leqembi" rel="noreferrer noopener">weekly maintenance dosing</a>.
A Prescription Drug User Fee Act (PDUFA) action date is August 31, 2025.
Biogen said Leqembi&#8217;s fourth-quarter global in-market sales of approximately $87 million, including U.S. in-market sales of approximately $50 million, represented good <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43659412/biogen-warns-lower-2025-revenue-inks-rd-funding-pact-with-royalty-pharma-for-late-stage-lupus-asset" rel="noreferrer noopener">continued sequential growth</a>.
In March, the CHMP issued an opinion that does not recommend that Eli Lilly and Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) donanemab be granted marketing authorization for early symptomatic Alzheimer&#8217;s disease. Lilly said it would seek <a target="_blank" href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-bi" rel="noreferrer noopener">re-examination by the CHMP</a>.
Kisunla (donanemab) is <a target="_blank" href="https://investor.lilly.com/news-releases/news-release-details/lillys-statement-about-chmp-opinion-issued-donanemab" rel="noreferrer noopener">used</a> to treat adults with early symptomatic Alzheimer&#8217;s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Price Action: BIIB stock is up 0.46% at $117.52 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44844823/trump-tariffs-roil-semiconductor-mineral-stocks-billionaire-dan-loebs-portfolio-faces-grueling-test" target="_blank" rel="noreferrer noopener">Trump Tariffs Roil Semiconductor, Mineral Stocks: Billionaire Dan Loeb&#8217;s Portfolio Faces Grueling Test</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Biotech

Large Cap

Health Care

General

BIIB

ESALY

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion

Several CEOs of the largest U.S. banks have recently expressed concerns about the economic fallout, market volatility and broader uncertainty resulting from President Donald Trump's<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44791485/bank-stocks-rebound-above-200-day-average-as-earnings-propel-dip-buyers"> new trade policies.&nbsp;</a>
Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) CEO David Solomon warned of uncertainty and potential turbulence ahead on the company&#8217;s earnings call Monday.&nbsp;
&#8220;This uncertainty around the path forward and fears over the potentially escalating effects of a trade war have created material risks to the U.S. and global economy,&#8221; Solomon told analysts<a href="https://www.benzinga.com/news/management/25/04/44802094/tariff-fears-pose-material-risks-to-us-and-global-economies-goldman-sachs-ceo-warns"> on the call</a>.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44841158/hongkong-post-stops-us-package-service-china-e-commerce-stocks-drop">Hongkong Post Stops US Package Service, China E-Commerce Stocks Drop&nbsp;</a>
Solomon also noted that he hears an even &#8220;greater sense of short-term concern&#8221; from CEOs located outside of the United States.&nbsp;
Last Friday, JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon <a href="https://www.benzinga.com/news/management/25/04/44774273/jpmorgan-ceo-jamie-dimon-expects-sp-500-growth-forecast-to-be-cut">pointed out </a>that the analyst community has lowered the consensus S&amp;P 500 growth forecast from 10% to only 5% growth in 2025. He then predicted the forecast to be lowered even further in the near term.&nbsp;
&#8220;My guess is that it [will] be zero and negative five probably the next month," Dimon said.&nbsp;
Dimon has also stated that<a href="https://www.benzinga.com/news/management/25/04/44717888/jpmorgan-jamie-dimon-warns-recession-now-likely-outcome"> a recession</a> is now a &#8220;likely outcome&#8221; due to the tariffs, and he expects many companies to withdraw or revise their forecasts because of the unpredictability. He emphasized that while the U.S. remains economically strong, the tariff uncertainty challenges that stability and could have lasting negative consequences. 
&#8220;Take a deep breath, negotiate some trade deals," Dimon urged the Trump administration last week. "It could get worse if we don&#8217;t make progress."
Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) CEO Brian Moynihan spoke about <a href="https://www.benzinga.com/news/management/25/04/44829134/bank-of-america-ceo-says-consumers-are-resilient-while-business-owners-worried-as-we-face-a-changing-economy">the effects</a> of economic uncertainty on the mindset of the bank's business-owner clients.&nbsp;
&#8220;They&#8217;re worried about how this will affect their businesses and where they should invest. And I think that&#8217;s slowing down some of their decision paths right now,&#8221; he said, adding that some are considering changing growth plans as well.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44817229/chinese-tiktok-influencers-expose-cheap-nike-lululemon-suppliers-to-bypass-trump-tariffs">Chinese TikTok Influencers &#8216;Expose&#8217; Cheap Nike, Lululemon Suppliers To Bypass Trump Tariffs&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

Politics

Management

Movers

Big Bank CEOs Weigh In On Trump's Turbulent Economy

Jefferies analyst Lloyd Byrne maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Hold and lowers the price target from $25 to $19.

Jefferies Maintains Hold on Bloom Energy, Lowers Price Target to $19

B. Riley Securities analyst William Woods reiterates Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $6 price target.

Reiteration

IMUX

B. Riley Securities Reiterates Buy on Immunic, Maintains $6 Price Target

DA Davidson analyst Gary Tenner maintains Hancock Whitney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) with a Buy and lowers the price target from $69 to $62.

DA Davidson Maintains Buy on Hancock Whitney, Lowers Price Target to $62

Roth MKM analyst Chip Moore maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral and lowers the price target from $26 to $20.

Roth MKM Maintains Neutral on Bloom Energy, Lowers Price Target to $20

Roth MKM analyst Eric Handler maintains AMC Entertainment Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) with a Neutral and lowers the price target from $3.25 to $3.

Roth MKM Maintains Neutral on AMC Entertainment Hldgs, Lowers Price Target to $3

Even after a sharp cooldown, the meme coin sector refuses to die quietly. With Fartcoin (CRYPTO: FARTCOIN) in the focus, traders say the meme coin mania might be entering a <a href="https://www.benzinga.com/money/best-crypto-meme-coins">stronger, more refined phase</a>.
What Happened: According to prominent crypto influencer <a href="https://x.com/waleswoosh/status/1912517666700497178">Wale Swoosh</a>, meme coins may be down from their highs, but they're far from out. 
Solana meme coins continue to generate massive volume roughly $2 billion daily on decentralized exchanges and $30 million in weekly NFT volume. 
While that&#8217;s down from the $22 billion peak, it&#8217;s still a sign of sustained interest.
Swoosh also highlighted the rise of LaunchLab, a launchpad by Solana's top decentralized exchange Raydium, as a possible catalyst for a sector revival. 
He draws parallels with NFTs: while volumes faded post-peak, the space didn't die—it evolved. 
The same may happen with meme coins: fewer, better projects with stronger infrastructure and better user experience.
Swoosh argues that meme coins are entering a more mature cycle, with smarter traders, better tooling, and a more discerning audience. The hype-driven frenzy might be over, but that could make room for quality projects to shine.
He adds: "The meme coin sector is gearing up for a second spring—less chaos, more structure and the same wild upside potential."
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44745800/millionaire-trader-rakes-in-1-million-on-the-meme-coin-thats-outpacing-dogecoin-shiba-inu">Millionaire Trader Rakes In $1 Million On The Meme Coin That&#8217;s Outpacing Dogecoin, Shiba Inu</a>
What's Next: Crypto trader Koala says he doesn't <a href="https://x.com/trader_koala/status/1912536703954481422">believe</a> legacy memes like Dogecoin and Shiba Inu will ever revisit their all-time highs, but he still sees potential for 200% to 300% gains from current levels. 
He expects the market to shift from broad-based euphoria to a more selective focus, where only a few meme coins dominate based on actual mindshare, not just noise.
In that environment, Fartcoin is shaping up as a potential breakout leader. With Bitcoin threatening a move above $90,000, some traders believe Fartcoin could ride the wave to a new all-time high before eventually passing the baton to the next viral coin.
CoinGecko data shows the total meme coin market cap sits at $48 billion, down 2.3% in the past 24 hours and off from recent $50 billion levels amid broader market weakness. 
Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is down 10%, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is down 8%, Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) dropped 30% after a sharp rally to new highs.
Still, both DOGE and SHIB maintain strong communities, and traders anticipate a near-term rebound, with SHIB buoyed by a <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44835956/shiba-inu-burns-60-million-shib-in-a-single-transaction-what-is-going-on">spike in burn rate</a> and positive on-chain metrics, and DOGE seeing <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44818627/dogecoin-whales-are-accumulating-is-a-breakout-imminent">increased whale accumulation</a> ahead of a potential bullish move.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44732651/how-arthur-hayes-turned-0-into-500-million-in-6-years-and-predicted-bitcoins-dump-to-76000">How Arthur Hayes Turned $0 Into $500 Million In 6 Years And Predicted Bitcoin&#8217;s Dump To $76,000</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

$TRUMP

Meme Coin Market Is 'Very Much Alive': Can Dogecoin, Shiba Inu, Fartcoin Bounce Back?

eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) stock moved <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">higher on Wednesday</a> after the company announced a global payment partnership aimed at enhancing user experience across its massive online marketplace.
The e-commerce giant revealed a <a target="_blank" href="https://www.ebayinc.com/stories/news/ebay-announces-global-payment-acquiring-partnership-with-checkout/" rel="noreferrer noopener">collaboration</a> with Checkout.com, a prominent international payment technology company. The partnership is intended to strengthen eBay&#8217;s digital payments infrastructure across its global network.
With billions of live listings and customers in nearly 200 countries, eBay said it continues to refine the core technology that underpins its platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44844696/whats-going-on-with-ionq-stock-today" rel="noreferrer noopener">What&#8217;s Going On With IonQ Stock On Wednesday?</a>
According to Avritti Khandurie Mittal, the company&#8217;s Vice President and General Manager of Global Payments and Financial Services, today&#8217;s shoppers prioritize security, speed, and ease of use—making efficient payment processing a top priority.
&#8220;The addition of Checkout.com to our partnership ecosystem highlights our continued commitment toward accelerating customer and business growth through uniquely eBay payments and financial services,&#8221; said Mittal, highlighting how the new alliance aligns with eBay&#8217;s vision to drive growth through innovation in financial services tailored for its unique ecosystem.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, EBAY stock has gained over 33% in the last one year. Investors can gain exposure to the stock via&nbsp;ProShares Online Retail ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>).
On April 8, JP Morgan analyst Doug Anmuth maintained a Neutral rating on eBay, <a target="_blank" href="https://www.benzinga.com/quote/EBAY/analyst-ratings" rel="noreferrer noopener">lowering the price forecast from&nbsp;$60&nbsp;to&nbsp;$54.</a>
Recently, eBay Ventures, eBay&#8217;s venture capital arm, has awarded US business Refiberd&nbsp;$300,000&nbsp;investment crowning them <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44713118/ebay-invests-300k-in-refiberd-to-drive-circular-fashion-solutions" rel="noreferrer noopener">eBay&#8217;s Circular Fashion Innovator of the Year.</a>
Price Action: EBAY shares are trading higher by 2.42% to $67.05&nbsp;at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44842205/tesla-is-2025s-biggest-mag-7-bruise-so-far-but-also-the-only-one-still-in-the-green" target="_blank" rel="noreferrer noopener">Tesla Is 2025&#8217;s Biggest Mag 7 Bruise So Far, But Also The Only One Still In The Green</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Equities

Markets

Tech

EBAY

ONLN

Why Is eBay Stock Trading Higher On Wednesday?

WIIM

BLUE

Carlyle Group and Bluebird Bio shares are trading lower. The company, along with SK Capital Partners, announced that the Beacon merger subsidiary has extended the expiration date to acquire the outstanding shares of Bluebird Bio.

In an environment where conventional income strategies are being pushed to their limits by persistent rate volatility and ambiguity, Simplify Asset Management is betting big on innovation. 
On Tuesday, the company introduced two <a href="https://www.benzinga.com/etfs">actively managed ETFs</a>, Simplify Barrier Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBAR#NYSE">SBAR</a>) and Simplify Target 15 Distribution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XV#NYSE">XV</a>), designed to provide investors structured, high-yielding income by leveraging the use of barrier put options.
In an era when fixed income returns continue to be squeezed and equity markets are volatile, these new funds are intended to offer stable income streams with well-defined downside risk — a hard-to-find combination in the current investing environment.
Also Read: <a href="https://www.benzinga.com/25/04/44812438/exclusive-argents-new-etfs-arent-chasing-ai-or-meme-stocks-heres-what-theyre-buying-instead">Exclusive: Argent&#8217;s New ETFs Are Not Chasing AI Or Meme Stocks, Here&#8217;s What They&#8217;re Buying Instead</a>
David Berns, Simplify&#8217;s CIO and co-founder, said the ETFs provide a degree of transparency and control that products simply cannot.
<h1 class="wp-block-heading">The Barrier Strategy</h1>
Both SBAR and XV write barrier put options, a derivative that exposes the writer to downside only in the event a certain level is violated, on a worst-of basket consisting of ETFs representing U.S. large-cap, small-cap and growth stocks. The &#8220;worst-of&#8221; strategy increases the potential of the option premium, which is subsequently redistributed to investors in the form of monthly income.
The funds' options are structured with predefined barrier levels, allowing investors to better understand their risk exposure upfront. Between expirations, fund prices will still fluctuate based on the options&#8217; market value, but actual downside losses are only realized if the worst-performing index crosses the barrier.
<h1 class="wp-block-heading">Inside The Funds</h1>
SBAR provides monthly income by blending U.S. Treasuries (with a target portfolio duration of less than two years) and a laddered 30-barrier put strategy. The objective is to provide higher yield relative to traditional bonds, with specified downside risk.
XV seeks a targeted 15% annualized rate of distribution, distributed monthly. Similar to SBAR, it also holds short-term Treasuries but dynamically adjusts barrier levels to back the income objective — in effect, presenting a more elastic income approach.
Both have a net expense ratio of 0.75% and are conceived as ongoing products, whose options are rolled in a systematic fashion, such that long-term exposure is provided without timing worries.
The launches are part of a larger shift in investor priorities — from pursuing returns to pursuing steady income and clearer risk transparency. With this expansion, Simplify broadens its line of products to over 35 ETFs and almost <a href="https://www.simplify.us/etfs">$7 billion</a> in assets under management, solidifying its position as a prime alternative ETF strategy provider.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44818473/etf-and-equity-trading-access-goes-live-on-kraken-as-platform-enters-traditional-markets">ETF, Equity Trading Access Goes Live On Kraken As Platform Enters Traditional Markets</a></li>
</ul>

New ETFs

ETFs

Simplify Exchange Traded Funds Simplify Barrier Income ETF

SBAR

Meet The New Income Machines: Simplify Debuts SBAR And XV

DA Davidson analyst Tom White maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Neutral and maintains $15 price target.

LYFT

DA Davidson Maintains Neutral on Lyft, Maintains $15 Price Target

Mizuho analyst Anthony Petrone maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Outperform and lowers the price target from $200 to $175.

GKOS

Mizuho Maintains Outperform on Glaukos, Lowers Price Target to $175

Teradyne shares are trading lower after Morgan Stanley cut its price target on the stock from $81 to $69 and maintained an Underweight rating.

Albertsons Companies shares are trading higher on possible continued strength after the company reported better-than-expected Q4 financial results yesterday. RBC Capital and Telsey Advisory Group reiterated Outperform ratings on the stock.

<h3>Gainers</h3>
<ul>
<li>Treasure Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) stock moved upwards by 58.2% to $3.29 during Wednesday's regular session. The company's market cap stands at $5.3 million. </li>
<li>Arena Group Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AREN#AMEX">AREN</a>) stock increased by 20.99% to $2.42. The company's market cap stands at $114.8 million. </li>
<li>iOThree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOTR#NASDAQ">IOTR</a>) stock rose 18.61% to $4.79. The company's market cap stands at $122.9 million. </li>
<li>CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) stock moved upwards by 18.32% to $3.1. The market value of their outstanding shares is at $178.6 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) shares rose 15.23% to $0.79. The market value of their outstanding shares is at $8.5 million. </li>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) stock rose 12.55% to $7.99. The market value of their outstanding shares is at $122.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock fell 33.6% to $0.17 during Wednesday's regular session. The company's market cap stands at $2.4 million. </li>
<li>TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) shares fell 32.48% to $0.26. The company's market cap stands at $7.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares decreased by 25.03% to $0.14. The company's market cap stands at $3.2 million. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock decreased by 16.5% to $0.37. The company's market cap stands at $9.7 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) stock declined by 13.34% to $0.59. The company's market cap stands at $5.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREN

BLMZ

CURI

IOTR

MCTR

MITQ

TNMG

TRUG

11 Communication Services Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock moved upwards by 73.0% to $3.34 during Wednesday's regular session. The market value of their outstanding shares is at $88.0 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock increased by 26.25% to $4.18. The market value of their outstanding shares is at $63.6 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) stock increased by 22.87% to $7.09. The company's market cap stands at $336.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares rose 21.48% to $1.09. The company's market cap stands at $18.0 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares rose 18.94% to $0.69. The company's market cap stands at $22.8 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares moved upwards by 18.11% to $2.87. The company's market cap stands at $13.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock declined by 34.4% to $0.13 during Wednesday's regular session. The market value of their outstanding shares is at $1.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 26.31% to $0.42. The market value of their outstanding shares is at $7.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock decreased by 19.52% to $1.37. The company's market cap stands at $18.8 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares declined by 19.05% to $1.87. The market value of their outstanding shares is at $3.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares declined by 17.24% to $1.78. The company's market cap stands at $55.4 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 15.84% to $0.01. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

BMRA

ICAD

JUNS

LGMK

MIRA

MSPR

PHIO

SXTC

SYRA

ZYBT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Press Releases

CLPS Incorporation to Announce Second Half and Full Year of Fiscal 2024 Financial Results

CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2024

Fintech

Dividends

CLPS Incorporation Declares Special Cash Dividend of $0.13 Per Share for Third Consecutive Fiscal Years

CLPS Incorporation Appoints Ms. Sarah Wu as Non-Executive Director of QCC to Drive Strategic Growth in Credit Card Solutions

Offerings

CLPS Incorporation Announces Filing of Registration Statement for Proposed Initial Public Offering of JAJI Global Incorporation

CLPS Incorporation Announces the Launch of Nibot RPA Product, Expanding Automation Services into the Global Market

CLPS Incorporation Announces the Establishment of CLPS AI Innovation Committee, Ushering in Next Generation Intelligent Solutions for Businesses

CLPS Incorporation to Announce First Half of Fiscal 2025 Financial Results

CLPS Incorporation Reports Financial Results for the First Half of Fiscal Year 2025

CLPS Incorporation Announces Establishment of Indonesia Subsidiary to Accelerate Regional Growth in Southeast Asia

Comments

CLPS

Notizie

Ultime notizie per CLPS (NASDAQ:CLPS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO